Analysts estimate for 2024 rising sales UCB

Tomorrow the Belgian company UCB will publish its past quarter results. For this year the company from Anderlecht could earn a total revenue around 5.81 billion euros. This is according to the average of the analysts' estimates. The expected revenue would be a record for the company. This is rather significant more than 2023's revenue of 5.25 billion euros.

Historical revenues and results UCB plus estimates 2024

The analysts expect for 2024 a net profit of 858 million euros. For this year the consensus of UCB 's result per share is a profit of 4.49 euros. Based on this the price/earnings-ratio is 41.22.

Per share the analysts expect a dividend of 1.42 euros per share. The dividend yield is then 0.77 percent. The average dividend yield of the pharmaceutical companies is an attractive 2.07 percent.

Newest target prices around 211 euros

UCB 's market capitalization is based on the number of outstanding shares around 35.09 billion euros.

Historical stock prices UCB period 2007-2024

On Tuesday the stock closed at 185.1 euros.

Analist.nl Nieuwsdienst: +31 084-0032-842
nieuws@analist.nl

Copyright analist.nl B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. Analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.